| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NovaBridge Biosciences | Efineptakin alfa (TJ107) | Glioblastoma multiforme (GBM) | Phase 2 | Trial Completed | Subcutaneous | Oncology |
| NovaBridge Biosciences | Olamkicept (TJ301) | Ulcerative colitis | Phase 2 | Trial Planned | Intravenous | Gastroenterology |
| NovaBridge Biosciences | Plonmarlimab (TJM2) | COVID-19 | Phase 2 | Ongoing | Intravenous | COVID-19 |
| Novan Inc. | SB204 | Acne vulgaris | Phase 3 | Topical | N/A | |
| Novan Inc. | SB204 | Acne vulgaris | Phase 3 | Topical | N/A | |
| Novartis AG | Denosumab biosimilar | Osteoporosis in postmenopausal women | BLA Filing | Subcutaneous | Osteoporosis | |
| Novartis AG | Abelacimab - (AZALEA-TIMI 71) | Atrial fibrillation | NDA Filing | Ongoing | Intravenous | Cardiology |
| Novartis AG | Zigakibart | IgA nephropathy (IgAN) | NDA Filing | Data Released | Intravenous | Immunology |